Holen Sie sich die Stockscreener-App
70.69
0.26%
0.18
Schlusskurs vom Vortag:
$70.51
Offen:
$71.19
24-Stunden-Volumen:
240.85K
Relative Volume:
0.06
Marktkapitalisierung:
$34.92B
Einnahmen:
$198.10B
Nettoeinkommen (Verlust:
$-6.45B
KGV:
-5.378
EPS:
-13.1443
Netto-Cashflow:
$7.11B
1W Leistung:
+8.15%
1M Leistung:
+7.09%
6M Leistung:
+81.26%
1J Leistung:
+98.34%
1-Tages-Spanne:
$70.22
$71.21
1-Wochen-Bereich:
$65.08
$71.01
52-Wochen-Spanne:
$31.63
$71.21
Centene Corp Stock (CNC) Company Profile
Firmenname
Centene Corp
Sektor
Branche
Telefon
(314) 725-4477
Adresse
7700 FORSYTH BLVD., ST LOUIS
Compare CNC vs UNH, CVS, ELV, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNC
Centene Corp
|
70.69 | 34.92B | 198.10B | -6.45B | 7.11B | -13.14 |
UNH
Unitedhealth Group Inc
|
402.61 | 361.38B | 450.13B | 14.91B | 23.62B | 15.55 |
CVS
Cvs Health Corp
|
92.84 | 118.75B | 407.94B | 2.90B | 7.39B | 2.2771 |
ELV
Elevance Health Inc
|
431.01 | 93.47B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
301.85 | 79.76B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
425.02 | 51.04B | 137.20B | 1.15B | 1.27B | 9.3439 |
Centene Corp Stock (CNC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-11 | Hochstufung | Argus | Hold → Buy |
| 2026-06-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-05-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-04-29 | Hochstufung | BofA Securities | Underperform → Buy |
| 2026-04-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-10-14 | Eingeleitet | Goldman | Sell |
| 2025-07-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-07-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-02 | Herabstufung | UBS | Buy → Neutral |
| 2025-06-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-02 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-08 | Hochstufung | Jefferies | Underperform → Hold |
| 2025-02-06 | Herabstufung | Argus | Buy → Hold |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-10 | Herabstufung | Jefferies | Hold → Underperform |
| 2024-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-03-21 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-09-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-06-20 | Eingeleitet | UBS | Neutral |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-13 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-30 | Eingeleitet | Argus | Buy |
| 2022-08-26 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-07-28 | Fortgesetzt | Barclays | Overweight |
| 2022-07-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-21 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Fortgesetzt | Bernstein | Outperform |
| 2022-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-07 | Fortgesetzt | Barclays | Overweight |
| 2022-01-06 | Fortgesetzt | JP Morgan | Overweight |
| 2021-12-14 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-13 | Bestätigt | BofA Securities | Buy |
| 2021-12-13 | Bestätigt | Credit Suisse | Neutral |
| 2021-12-13 | Bestätigt | Mizuho | Neutral |
| 2021-12-13 | Bestätigt | Oppenheimer | Outperform |
| 2021-12-13 | Bestätigt | Stephens | Overweight |
| 2021-12-13 | Bestätigt | Truist | Buy |
| 2021-12-13 | Bestätigt | Wells Fargo | Overweight |
| 2021-12-13 | Bestätigt | Wolfe Research | Outperform |
| 2021-11-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-09-10 | Eingeleitet | Cowen | Outperform |
| 2021-07-09 | Eingeleitet | Seaport Global Securities | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Overweight |
| 2021-05-11 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-03-10 | Eingeleitet | Mizuho | Neutral |
| 2021-01-21 | Fortgesetzt | Goldman | Neutral |
| 2021-01-15 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-22 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-02-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-01-28 | Bestätigt | Bernstein | Outperform |
| 2020-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-05-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-14 | Eingeleitet | Stephens | Overweight |
| 2018-10-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-07-18 | Fortgesetzt | Citigroup | Neutral |
| 2017-12-18 | Bestätigt | Jefferies | Buy |
| 2017-09-13 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-06-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-05-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-04-05 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2017-02-08 | Bestätigt | Barclays | Overweight |
| 2017-02-07 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-01-04 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Centene Corp Aktie (CNC) Neueste Nachrichten
Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth? - Zacks Investment Research
Centene's Gold Card Push Could Ease CostsBut Will Savings Follow? - Zacks Investment Research
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Zacks Investment Research
How Evidence Can Guide Prevention Investments - Centene Corporation
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Yahoo Finance
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Zacks Investment Research
Form 4 Centene Corp For: 11 October By Investing.com - Investing.com India
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not (NYSE:CNC) - Seeking Alpha
Centene Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Humana rebounds, Aetna slips: Winners and losers in the 2027 MA star ratings - Fierce Healthcare
Cantor Fitzgerald reiterates Centene stock Overweight rating at $75 - Investing.com
ACA plan provider takes the top spot on the managed care list - The Business Journals
Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? - Zacks Investment Research
Centene Corp To Redeem $568.66 Mln Of 4.25% Notes Due 2027 On Oct 23, 2026 - TradingView
NH Healthy Families Earns a 4.0 out of 5-Star NCQA Medicaid Health Plan Rating - Centene Corporation
Centene to redeem $568.7M of 4.25% notes due 2027 on Oct. 23 - TradingView
Earnings Preview: What to Expect From Centene's Report - Barchart.com
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Zacks Investment Research
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Zacks Investment Research
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Yahoo Finance
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - TradingView
Centene to Offer Expanded Health Access to Eligible Ambetter Members - www.marketscreener.com
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri - PR Newswire
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated - Zacks Investment Research
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated - Yahoo Finance
Buy 5 Growth Stocks to Boost Your Portfolio in Q4 After a Mixed Q3 - Zacks Investment Research
Centene Corp (XBUL:QEN) Stock Price, Trades & News - GuruFocus
Oscar Health Trading at a Premium: Why Should You Still Buy It? - Zacks Investment Research
Centene Corp. stock gains 1.11 percent ahead of Q3 results - AD HOC NEWS
Centene reaffirms 2026 earnings guidance: Centene stock gains 1.68 percent - AD HOC NEWS
Are Investors Undervaluing Centene (CNC) Right Now? - Zacks Investment Research
Are Investors Undervaluing Centene (CNC) Right Now? - Yahoo Finance UK
Are Investors Undervaluing Centene (CNC) Right Now? - Yahoo Finance
Centene Corp (CNC) Stock Up 3.3% and Still Undervalued -- GF Sco - GuruFocus
Centene Corp. stock outperforms competitors on strong trading day - MarketWatch
Centene Corp. stock outperforms competitors on strong trading day - MarketWatch
Centene stock after-hours at EUR 55.62: plus 2.53 percent - AD HOC NEWS
Centene Corporation (CNC) - Yahoo! Finance Canada
Vance's fraud crackdown may raise costs for US health insurers, enrollees - marketscreener.com
Centene Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Centene Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Centene (CNC): Pricing Actions and Profit Stabilization Drive Earnings Recovery - Yahoo Finance
Centene Corporation (CNC) Jumped on Beat-and-Raise Earnings Quarter - Yahoo Finance
Cantor Fitzgerald reiterates Centene stock rating on margin recovery - Investing.com
Best Growth Stocks to Buy for October 1st - Zacks Investment Research
Zacks.com featured highlights include Banco Macro, Centene, Enersys, Gibraltar Industries and Kennametal - Zacks Investment Research
Zacks.com featured highlights include Banco Macro, Centene, Enersys, Gibraltar Industries and Kennametal - Yahoo Finance
A 583-share award at $0 goes to Centene (CNC) director Theodore R. Samuels II. - Stock Titan
After a 603-share grant, Centene (CNC) director Kenneth Tanji holds 13,093 shares. - Stock Titan
A director received 864 shares at Centene (CNC) on September 30, 2026. - Stock Titan
Finanzdaten der Centene Corp-Aktie (CNC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Centene Corp-Aktie (CNC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KOSTER CHRISTOPHER | Officer |
Aug 26 '26 |
Proposed Sale |
66.90 |
56,500 |
3,779,852 |
0 |
| Burdick Kenneth A | Former Director |
Aug 26 '26 |
Proposed Sale |
65.00 |
43,600 |
2,834,000 |
0 |
| KOSTER CHRISTOPHER | Secretary & General Counsel |
Aug 18 '26 |
Sale |
65.36 |
47,603 |
3,111,332 |
305,354 |
| KOSTER CHRISTOPHER | Officer |
Aug 18 '26 |
Proposed Sale |
65.36 |
47,603 |
3,111,262 |
0 |
| Burdick Kenneth A | Former Director |
Aug 05 '26 |
Proposed Sale |
68.15 |
100,000 |
6,815,182 |
0 |
| Burdick Kenneth A | Director |
Jun 10 '26 |
Proposed Sale |
64.55 |
80,000 |
5,164,227 |
0 |
| Burdick Kenneth A | Director |
Jun 10 '26 |
Sale |
64.55 |
80,000 |
5,164,000 |
197,086 |
| Burdick Kenneth A | Director |
Dec 04 '25 |
Sale |
39.00 |
32,796 |
1,279,044 |
272,365 |
| Burdick Kenneth A | Director |
Dec 04 '25 |
Proposed Sale |
39.00 |
32,796 |
1,279,044 |
0 |
| Burdick Kenneth A | Director |
Dec 03 '25 |
Sale |
39.04 |
33,211 |
1,296,557 |
305,161 |
1.66%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):